Company to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026Expanded clinical advisory team with ...
SAN FRANCISCO, Nov. 14, 2025 /PRNewswire/ — Builder.io today announced Fusion 1.0, the first AI agent that connects the ...
AI has changed how teams develop software products. Instead of writing every line inside a traditional IDE, developers now describe what they want and let...Read More The post 15 Best Vibe Coding ...
Cursor announced a $2.3 billion Series D funding round today, valuing the AI-powered code editor at $29.3 billion—nearly triple its $9.9 billion valuation from just five months earlier. The round was ...
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ('Adial” or the 'Company”), a clinical-stage biopharmaceutical company focused on ...
Management revised projected enrollment completion to the first half of 2026, citing "delays in the activation of the new ...
The Wells family, which has farmed land in Riverhead for 12 generations, was sifting through the ashes Thursday of a ...
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for ...
A new Merck pill called enlicitide slashes levels of harmful LDL cholesterol by up to 60%, similar to injectable PCSK9 drugs ...
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio ...
(Nasdaq:GCTK) today announced a slight delay in its plans to submit its long-term glucose monitor to the FDA for IDE.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback